Furthermore, an open-label, multicenter, ongoing trial (NCT03099564) is assessing the safety and the effects of pembrolizumab (anti-PD-1 mAb) plus the radiology procedure with yttrium-90 in patients with a poor prognosis of HCC, not eligible for liver transplant or surgical resection [80]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.